The alcohol use disorder (AUD) market is projected to expand at a 12.1% compound annual growth rate (CAGR) from 2026 to 2036, driven by unmet clinical needs and the development of novel therapies targeting new mechanisms like the 5-HT3 pathway and NOP receptor. Key companies including Adial Pharmaceuticals and Eli Lilly are advancing promising drugs such as AD04 and Brenipatide, which are expected to reshape treatment options. Increased public awareness, reduced stigma, and regulatory approvals are boosting diagnosis and treatment adoption, particularly in the US where the market was valued at $1.1 billion in 2025. These innovations signal significant growth and improved care standards in the AUD treatment landscape over the next decade.
Novo Nordisk and Eli Lilly are competing in the obesity drug market with their GLP-1 pills, Wegovy and Foundayo, respectively. Both companies are preparing for Medicare to cover these drugs for weight loss at $50 per month starting July 1, which coul...
Eli Lilly's stock surged in premarket trading following positive results from a Phase 3 trial of its next-generation weight-loss drug, retatrutide. Presented at the American Diabetes Association conference, the trial showed that patients lost an aver...
A curated list of 50 high-quality dividend growth stocks has been tracked since September 1, 2024, focusing on valuation and future return potential. Year-to-date, this group underperformed broad indexes but included standout performers like LRCX and...
Eli Lilly's Foundayo (orforglipron) showed significant weight loss results in women across all menopause stages in the ATTAIN-1 and ATTAIN-2 trials, including those with type 2 diabetes. Women lost up to 30.4 lbs (14.4%) in perimenopause and up to 28...
The Dow Jones Industrial Average reached a new record after a 2% gain, with the S&P 500 also rising 0.4%. Healthcare stocks led the market rally, driven by strong gains in insurers like Humana and Centene, and drugmakers such as UnitedHealth Group an...
